Tenecteplase Thrombolysis in Posterior Circulation Stroke

F Alemseged; BCV Campbell

Journal article

Tenecteplase Thrombolysis in Posterior Circulation Stroke

F Alemseged, BCV Campbell

Frontiers in Neurology | Published : 2021

DOI: 10.3389/fneur.2021.678887

Download PDF

Abstract

One in five ischaemic strokes affects the posterior circulation. Basilar artery occlusion is a type of posterior circulation stroke associated with a high risk of disability and mortality. Despite its proven efficacy in ischaemic stroke more generally, alteplase only achieves rapid reperfusion in ~4% of basilar artery occlusion patients. Tenecteplase is a genetically modified variant of alteplase with greater fibrin specificity and longer half-life than alteplase, which can be administered by intravenous bolus. The single-bolus administration of tenecteplase vs. an hour-long alteplase infusion is a major practical advantage, particularly in “drip and ship” patients with basilar artery occlus..

View full abstract

University of Melbourne Researchers

Fana Alemseged Author

Bruce Campbell Author

Related Projects (4)

EXTEND-IA randomized trial of intra-arterial clot retrieval in ischemic stroke

Most strokes are caused by a blocked blood vessel in the brain. Current treatments to dissolve the blockage improve recovery for many patien..

OPTIMIZING STROKE THERAPY - ADVANCED BRAIN IMAGING AND REPERFUSION THERAPIES

Most stroke is due to a blocked blood vessel reducing blood flow to the brain. This research aims to optimize fast restoration of blood flow..

SAVING BRAIN AND CHANGING PRACTICE IN STROKE

Stroke outcomes directly relate to brain tissue rescue. We have contributed to changes in clinical practice through many clinical trials of ..

OPTIMIZING STROKE THERAPY - ADVANCED BRAIN IMAGING AND REPERFUSION THERAPIES

Most stroke is due to a blocked blood vessel reducing blood flow to the brain. This research aims to optimize fast restoration of blood flow..

Grants

Awarded by Medtronic

Funding Acknowledgements

BC reported research support from the National Health and Medical Research Council of Australia (GNT1043242, GNT1111972, and GNT1113352), Royal Australasian College of Physicians, Royal Melbourne Hospital Foundation, National Heart Foundation (Future Leaders Fellowship 100782), National Stroke Foundation of Australia and unrestricted Grant funding for the EXTEND-IA trial (Extending the Time for Thrombolysis in Emergency Neurological Deficits -Intra-Arterial) to the Florey Institute of Neuroscience and Mental Health from Covidien (Medtronic).